AstraZeneca PLC's bid to establish its PD-1/L1 inhibitor Imfinzi (durvalumab) as a standard treatment in the future for early-stage lung cancer has been boosted by plans to start a late-stage trial of the drug in combination with Incyte Corp.'s closely-watched indoleamine 2, 3-dioxygenase (IDO) checkpoint inhibitor epacadostat.
The two companies will co-fund a Phase III trial in patients with locally-advanced (ie Stage III), unresectable non-small cell lung...






